OneOncology continues to expand its network of community-based oncology practices, now serving millions of patients across the United States. The events of 2025 underscored how deeply government policy shapes healthcare affordability and delivery — and how contentious that environment has become.

From July 2025, the enacted budget reconciliation package, “One Big, Beautiful Bill,” significantly reduced funding for both Medicaid and Affordable Care Act exchange subsidies. Many issues remain unresolved, and affordability including in healthcare is expected to be a defining political issue in this year’s midterm elections. The reconciliation bill presents real challenges for many sites of care, including both independent oncology practices and large hospital systems. Recent elections have also elevated affordability as a bipartisan priority.

In this complex environment, OneOncology continues to proactively advocate, including regular engagement with policymakers and frequent visits to Capitol Hill and state Capitols. We have a strong story to tell — one grounded in innovation, patient access, affordability, value-based care, and a compelling long-term vision. Our value proposition includes expanding clinical research, advancing precision medicine, providing robust cyber support for practices, and developing generic drug reserves to help mitigate shortages. While we advocate on many specific policy issues, our discussions with policymakers always begin with a clear demonstration of the value independent oncology brings to patients and to the healthcare system — including our unique role bringing cancer care and clinical trials closer to patients, which reduce access barriers, especially in rural and medically underserved communities.

This fall, I was honored to be elected the second President of the American Independent Medical Practice Association (AIMPA), of which OneOncology was an original founding member. In just two years, AIMPA has grown to represent more than 12,000 physicians nationwide. The organization has made an early impact through national media engagement, op-eds, and direct advocacy on Capitol Hill. AIMPA continues to build momentum while advocating on issues such as the Physician Fee Schedule, the role of MSOs, and insurer downcoding.

Drug pricing remains central to current health policy debates. The first ten Medicare Part D drugs subject to Inflation Reduction Act price negotiations took effect in early 2026, which will significantly reduce Medicare reimbursement and threaten commercial reimbursement via changes to ASP. OneOncology remains deeply concerned about the implementation of Maximum Fair Prices for Part B drugs beginning in 2028, which is projected to significantly reduce reimbursement for physician-administered medications. We continue to engage with lawmakers to pursue legislative solutions that preserve the viability of independent practices. In addition, recent CMMI proposals — including the GLOBE and GUARD models — signal further expansion of price controls across Parts B and D. While we were encouraged by the stated intent to maintain physician reimbursement neutrality, key implementation details remain under review.

Looking ahead, OneOncology will continue to advocate for critical issues impacting independent specialty care and the patients we serve. We are deeply grateful for the support and engagement of our exceptional physician network as we navigate the challenges — and opportunities — of the year ahead.